The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.

The drug, RHB-204, is a next-generation formulation of a separate candidate from RedHill, RHB-104, which showed positive results in a Phase III trial.

Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeat the disease.

PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.

The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.

Coeptis previously held limited co-development rights to GEAR. In conjunction with the new license agreement, Coeptis has formed a majority-owned subsidiary, called GEAR Therapeutics, to evaluate GEAR ...